PRTG Overview

Company Overview: AlphaTON Capital, formerly Portage Biotech Inc., is set to trade under the ticker "ATON" starting September 4, 2025, focusing on acquiring TON tokens and developing a digital asset treasury linked to Telegram's extensive user base.

Leadership Appointment: Brittany Kaiser has been appointed as CEO and Board Member, bringing her expertise in data protection and blockchain to lead the company's strategy in the rapidly evolving digital asset market.

Operational Strategy: The company aims to generate returns through a treasury strategy that includes acquiring TON tokens, managing staking operations, and developing applications within the Telegram ecosystem, targeting decentralized finance and gaming sectors.

Financing and Growth Plans: AlphaTON Capital has secured approximately $38.2 million through a private placement and a $35 million loan facility to fund its acquisition of TON tokens and establish its treasury operations, positioning itself for significant growth in the digital asset space.

Financial Performance: Portage Biotech reported a significant reduction in net loss to approximately $6.8 million for the fiscal year ending March 31, 2025, down from $75.4 million the previous year, largely due to decreased operating expenses and non-cash losses related to impairments.

Operational Changes: The company experienced a 75% decrease in research and development costs, primarily due to paused clinical trials and reduced headcount, while general and administrative expenses also saw a decline of about 25%.

Worthington Steel Financial Results: Worthington Steel, Inc. shares surged 15.7% in pre-market trading after reporting fourth-quarter earnings of $1.05 per share, exceeding analyst expectations of 82 cents.

Pre-Market Stock Movements: Several stocks saw significant movements in pre-market trading, with Vor Biopharma Inc. rising 105.6% due to a licensing agreement, while Reviva Pharmaceuticals Holdings Inc. fell 30.2% following a proposed public offering.

Compliance with Nasdaq: Portage Biotech Inc. has received confirmation from Nasdaq that it has regained full compliance with listing requirements, resolving previous non-compliance issues.

Company Overview and Stock Performance: The company, focused on developing immuno-oncology therapies, is currently trading at $6.31, reflecting a 9.68% increase.

Compliance with Nasdaq Requirements: Portage Biotech Inc. has received formal notice from The Nasdaq Stock Market confirming its compliance with all requirements for continued listing on the Nasdaq Capital Market as of June 24, 2025.

Company Overview: Portage Biotech is a clinical-stage immuno-oncology company focused on developing novel biologics to enhance the immune system's ability to combat cancer.

Portage Biotech and Compedica Agreement: Portage Biotech has entered a Subscription Agreement with Compedica, issuing 625,000 shares valued at $5 million in exchange for shares of Compedica, giving Compedica a 27.4% stake in Portage. The agreement includes a commitment for Portage to invest in Compedica's equity in future funding rounds.

Focus on Diabetic Foot Ulcers: Compedica aims to commercialize its OptiPulse medical device for treating diabetic foot ulcers, a significant health issue affecting millions globally. The company plans to publish clinical trial results by Q4 2025 and expects to launch the device commercially in North America in early 2026.